ProShare Advisors LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

ProShare Advisors LLC increased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 33.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 20,915 shares of the biotechnology company's stock after buying an additional 5,290 shares during the quarter. ProShare Advisors LLC's holdings in Blueprint Medicines were worth $1,824,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in Blueprint Medicines by 69.7% in the fourth quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company's stock valued at $373,000 after purchasing an additional 1,756 shares during the period. Fifth Third Bancorp increased its position in shares of Blueprint Medicines by 207.5% during the 4th quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company's stock worth $268,000 after purchasing an additional 2,075 shares during the last quarter. KBC Group NV increased its position in shares of Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 1,023 shares during the last quarter. R Squared Ltd purchased a new stake in Blueprint Medicines in the 4th quarter valued at about $51,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in Blueprint Medicines by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,470 shares of the biotechnology company's stock valued at $1,175,000 after buying an additional 1,287 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BPMC shares. JMP Securities reiterated a "market outperform" rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Needham & Company LLC dropped their price target on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Wedbush reiterated an "outperform" rating and set a $128.00 price target on shares of Blueprint Medicines in a research report on Thursday, May 1st. Scotiabank started coverage on Blueprint Medicines in a research report on Friday, March 7th. They set a "sector outperform" rating and a $150.00 price target for the company. Finally, Morgan Stanley started coverage on Blueprint Medicines in a research report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target for the company. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Blueprint Medicines has a consensus rating of "Moderate Buy" and an average price target of $126.56.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the firm's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the sale, the chief operating officer now directly owns 69,266 shares in the company, valued at $6,581,655.32. This trade represents a 3.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ariel Hurley sold 2,752 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the sale, the insider now owns 16,944 shares in the company, valued at approximately $1,747,434.72. This represents a 13.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,777 shares of company stock worth $1,256,490 over the last ninety days. Corporate insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Up 1.2%

Shares of NASDAQ BPMC traded up $1.16 during mid-day trading on Friday, hitting $101.50. The company had a trading volume of 353,347 shares, compared to its average volume of 781,410. The company has a market capitalization of $6.56 billion, a PE ratio of -93.98 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a 1-year low of $73.04 and a 1-year high of $121.90. The business's 50-day simple moving average is $90.77 and its 200 day simple moving average is $94.66.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The business had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter in the prior year, the business earned $1.40 earnings per share. The firm's quarterly revenue was up 55.5% on a year-over-year basis. On average, analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.